BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38461331)

  • 1. Machine learning developed a CD8
    Chen R; Zheng Y; Fei C; Ye J; Fei H
    Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer.
    Wang L; Chen X; Song L; Zou H
    Anal Cell Pathol (Amst); 2023; 2023():7365503. PubMed ID: 37868825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
    Han X; Yang L; Tian H; Ji Y
    Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learning.
    Zhao B; Pei L
    BMC Med Genomics; 2023 Oct; 16(1):230. PubMed ID: 37784081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
    Feng Q; Lu H; Wu L
    PLoS One; 2023; 18(9):e0291645. PubMed ID: 37725627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Zhang W; Wang S
    Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning constructs a T cell-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
    Zhang Y; Pei L
    Aging (Albany NY); 2024 Feb; 16(4):3332-3349. PubMed ID: 38345575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
    Wang D; Ding D; Ying J; Qin Y
    IET Syst Biol; 2023 Dec; 17(6):366-377. PubMed ID: 37935646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between tumor mutation burden and immune infiltration in ovarian cancer.
    Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.
    Ding D; Wang L; Zhang Y; Shi K; Shen Y
    Transl Oncol; 2023 Dec; 38():101784. PubMed ID: 37722290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.
    Li F; Feng Q; Tao R
    Medicine (Baltimore); 2024 Mar; 103(10):e37314. PubMed ID: 38457593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
    Deng Z; Feng Q; Zhao D; Huang Z
    Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
    Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
    Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
    Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
    Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
    Ye J; Tian W; Zheng B; Zeng T
    Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
    Wang T; Han L; Xu J; Guo B
    Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Li Z; Guo M; Lin W; Huang P
    Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.